Simcere Pharmaceutical Group Ltd (2096) fair value: what the stock is really worth
As of Nov 13, 2026: fair value (intrinsic value) of Simcere Pharmaceutical Group Ltd stock HK$12.62, price HK$10.58, upside +19.3%, quality 69 out of 100. Rating: undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Simcere Pharmaceutical Group Ltd
2096 · HKSolid company, but only slightly cheap (16% below fair value) and falling price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 14, 2026.
How to read this chart
60‑month range HK$4.70 – HK$14.49 · fair‑value band HK$8.33 – HK$16.27 · the HK$10.58 price screens below the HK$12.62 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 14, 2026.
Every Wednesday you see whether Simcere Pharmaceutical Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Simcere Pharmaceutical Group Limited, an investment holding company, engages in the research, development, manufacture, and sale of pharmaceutical products to distributors, pharmacy chains, and other pharmaceutical manufacturers in China.
Show moreShow less
It develops Endostar, a recombinant human endostatin injection; ENWEIDA, an envafolimab injection; Leruiping, a fully human monoclonal antibody targeting IL-4Ra; Zemprocitinib a highly selective JAK1 inhibitor; and Xianlinda, an inhibitor for influenza polymerase acidic protein that has completed Phase 3 clinical trials.
The company also develops SIM0270, a new-generation oral SERD with blood-brain barrier penetration characteristics; Denlorlatinib; SIM0395, a BBB-penetrant inhibitor of the PI3K/mTOR pathway; and deuterated remdesivir hydrobromide dry suspension that are in Phase 3 clinical trial, as well as Sanbexin an injection new indication; Sanbexin a sublingual tablets; and SIM0278, a Fc fusion protein (IL2muFc) with an IL2 mutein of regulatory T cells that is in Phase 2 clinical trials.
It develops SIM0237, an anti-PD-L1 monoclonal antibody fused with IL-15/IL15RXa sushi protein; Enzeshu, a suvemcitug for injection; SIM0500, a humanized trispecific antibody that targets GPRC5D/BCMA/CD3; SIM0508, a small molecule inhibitor; SIM0505, a CDH6-targeting ADC molecule; SIM0686, an ADC drug targeting FGFR2b; SIM0609, a new antibody-drug conjugate targeting CDH17; SIM0610, a bispecific antibody-drug conjugate; SIM0532, an oral, non-covalent pan-RAS inhibitor; SIM0323; and SIM0811, a small-molecule plasminogen allosteric activator that are in Phase 1 clinical trial.
The company develops SIM0613; SIM0709; SIM0689; SIM0688; SIM0518; SIM0616; SIM0611; SIM0815; SIM0712; SIM0725; SIM0708; SIM0721; and SIM0722 that are in pre-clinical stage.
It offers pharmaceutical ingredients; production support facility; consulting and technology; promotion; and property management. The company was founded in 1995 and is headquartered in Nanjing, China.
Stock analysis
Simcere Pharmaceutical Group Ltd (2096) currently trades at HK$10.58, while our model-based Fair Value estimate is HK$12.62, implying the stock looks roughly 16% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of HK$14.18 per share, and 16 of the 26 models we run sit above the HK$10.58 price.
Bear case: the Dividend Discount group reads lowest at HK$5.37, and 10 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: HK$8.33 (bear) to HK$16.27 (bull), the price of HK$10.58 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 69/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Simcere Pharmaceutical Group Ltd reported revenue of 7.7B CNY in FY2025 versus 5.0B CNY in FY2021, a compound +11.5%/yr. Reported net income was 1.3B CNY in FY2025, compounding −2.8%/yr from FY2021.
Key figures
Market cap HK$27.1B (≈ $3.4B) Mid · P/E ratio 15.7 · P/S ratio 2.73 · Dividend yield 1.7% · Net margin 17.4% · Return on equity 18.8% · Return on assets (EBIT) 9.3% (5-year average) · Operating margin 22.8%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 71 out of 100 (low confidence).
What moves the price
The share trades about 23% below its 52-week high and 14% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 19%, 2096 screens cheaper than that median.
Fair Value models
All 26 models by family
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Growth Forecast
Watch 2096, get fair value alerts →
Earlier news
- Lynk Pharmaceuticals Announces Commercialization Collaboration with Simcere for Zemprocitinib in Dermatology Indications, Further Expanding
- Simcere Pharmaceutical Group (SEHK:2096) Stock Looks Undervalued At Today’s Price
- Simcere Zaiming Enters Exclusive License Agreement with Roche for SIM0660 Global Development
- Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients wi
Compare Simcere Pharmaceutical Group Ltd with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 603 stocks
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Net margin by industry
- P/B ratio by industry
- Stock screener with 62 metrics
- Undervalued stocks: Hong Kong Stocks
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Zoetis Inc ZTS | $83.82 | $113.53 | +35% | vs 2096 |
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥48.07 | ¥53.04 | +10% | vs 2096 |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,880 | ₹1,983 | +5% | vs 2096 |
| Haleon plc HLN | $9.17 | $8.47 | −8% | vs 2096 |
| Merck KGaA MRK | €149.60 | €108.83 | −27% | vs 2096 |
| Galderma Group GALD | CHF 191.40 | CHF 112.30 | −41% | vs 2096 |
| Takeda Pharmaceutical Company TAK | $21.43 | $11.20 | −48% | vs 2096 |
| Sandoz Group SDZ | CHF 84.60 | CHF 40.54 | −52% | vs 2096 |
| Teva Pharmaceutical Industries Limited TEVA | $44.50 | $20.74 | −53% | vs 2096 |
| Divi's Laboratories Limited DIVISLAB | ₹11,442 | ₹1,567 | −86% | vs 2096 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Simcere Pharmaceutical Group Ltd (2096) overvalued or undervalued?
What is the fair value of 2096?
What is the quality score of 2096?
What is the price target for Simcere Pharmaceutical Group Ltd (2096)?
What is the Simcere Pharmaceutical Group Ltd stock forecast for 2026?
What is the revenue of Simcere Pharmaceutical Group Ltd (2096)?
Does Simcere Pharmaceutical Group Ltd pay a dividend?
How much is the dividend of Simcere Pharmaceutical Group Ltd (2096) and when is the ex-dividend date?
What growth is priced into Simcere Pharmaceutical Group Ltd (2096)?
What discount rate (WACC) does the fair value of 2096 use?
What is a reverse DCF?
How much growth has Simcere Pharmaceutical Group Ltd (2096) delivered so far?
How fast is the sector of Simcere Pharmaceutical Group Ltd (2096) growing?
What is the free cash flow yield of Simcere Pharmaceutical Group Ltd (2096)?
What is the intrinsic value of Simcere Pharmaceutical Group Ltd (2096)?
Is Simcere Pharmaceutical Group Ltd stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 2096?
How much is Simcere Pharmaceutical Group Ltd worth?
What do the bullish and bearish scenarios say about 2096?
What is the P/E ratio of 2096?
How solid is the balance sheet of Simcere Pharmaceutical Group Ltd (2096)?
How far is 2096 from its 52-week high?
Which stocks are comparable to Simcere Pharmaceutical Group Ltd?
Is Simcere Pharmaceutical Group Ltd stock attractive at the current price?
How is the fair value of 2096 calculated?
Is it still worth investing in stocks now?
What is the share price of Simcere Pharmaceutical Group Ltd (2096)?
What should I pay attention to with Simcere Pharmaceutical Group Ltd right now?
Key figures of Simcere Pharmaceutical Group Ltd
How large is the market capitalisation of Simcere Pharmaceutical Group Ltd (2096)?
What is the P/S ratio of Simcere Pharmaceutical Group Ltd (2096)?
What is the dividend yield of Simcere Pharmaceutical Group Ltd (2096)?
What is the net margin of Simcere Pharmaceutical Group Ltd (2096)?
What is the return on equity of Simcere Pharmaceutical Group Ltd (2096)?
What is the EBIT return on assets of Simcere Pharmaceutical Group Ltd (2096)?
What is the operating margin of Simcere Pharmaceutical Group Ltd (2096)?
How fast is revenue growing at Simcere Pharmaceutical Group Ltd (2096)?
How fast are earnings growing at Simcere Pharmaceutical Group Ltd (2096)?
How much net cash does Simcere Pharmaceutical Group Ltd (2096) hold?
Watch Simcere Pharmaceutical Group Ltd in the live analysis
One click puts Simcere Pharmaceutical Group Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.